Project Grant HT94252510707
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award in the amount of $906,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant titled "Defining and Targeting Cancer Cell-Intrinsic Vulnerabilities in Renal Cell Carcinoma" will be performed by the Medical University of South Carolina (MUSC) from August 1, 2024 to July 31, 2027. Through this funding, MUSC will conduct innovative biomedical research to study novel therapies...
The Medical University of South Carolina (MUSC) was awarded a $792,245 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "LEVERAGING LINEAGE ADDICTION: NUCLEAR DELIVERY OF THERAPEUTIC TRANSGENES RESPONSIVE TO ONCOGENIC TRANSCRIPTION FACTOR OVEREXPRESSION," will fund research focused on developing innovative gene therapy approaches to treat various medical conditions. The award has a performance...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
This $1,038,931 federal Project Grant was awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant funds research conducted by The Medical University of South Carolina (MUSC) to study SETD2 deficiency and its potential to increase sensitivity to BCL-XL inhibition, which may lead to new treatment approaches. The award has a performance period from September 30, 2024 to September 29, 2028. MUSC, a public university and major...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The Medical University of South Carolina (MUSC) was awarded a $1,503,880 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research into the function of the ARIH1 gene in epithelial-mesenchymal transition (EMT) and tumorigenesis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The Defense Health Agency awarded a $755,001 Project Grant to The Medical University of South Carolina (MUSC) under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, running from July 1, 2023 to June 30, 2026, supports research on microsomal glutathione transferase as a new target in melanotic melanoma. As a public institution of higher education, MUSC conducts biomedical research and provides healthcare services, with a mission to preserve and optimize...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
The Department of the Army Medical Command awarded a $1,419,356 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to develop novel immunotherapy approaches to suppress cancer metastasis and recurrence in bone. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...